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Abstract 
Protons and heavier ions have an increased relative biological effectiveness (RBE) 
compared to photons. While variable RBE models are applied clinically in carbon 
ion therapy, the RBE in proton therapy is accounted for clinically by applying a 
constant RBE of 1.1. However, an increasing amount of experimental and clinical 
data show that also the proton RBE varies spatially within the patient. In addition, 
the existing carbon ion RBE models give substantially different RBE-weighted dose 
(often referred to as biological dose) distributions for the same irradiation 
scenarios. Improving the current RBE calculations is therefore crucial for the 
treatment received by patients. In this thesis, variables affecting the RBE and 
biological dose models were studied using the FLUKA Monte Carlo code.  
In the first part of the thesis, a low-energy proton beam cell irradiation 
experiment at the Oslo Cyclotron Laboratory (OCL) was implemented in FLUKA 
(Paper I). Applying the FLUKA implementation, the dose and linear energy transfer 
(LET) (both the dose-averaged LET (LETd) and LET spectra) were estimated in 
potential cell irradiation positions. The LETd values increased along the beam path, 
up to approximately 40 keV/μm in the distal dose-fall off. The LET spectra became 
narrower with depth in water. Comparisons with a simulated 80 MeV proton beam 
showed that the OCL beam had significantly higher LETd values and much narrower 
LET spectra for the same LETd values. The FLUKA implementation of the OCL beam 
demonstrated the importance of having proper proton beam characteristics to 
achieve accurate RBE versus LET data. 
In the second part of the thesis, the RBE model applied clinically in carbon 
ion therapy in Japan (the microdosimetric kinetic model, MKM) was implemented 
in FLUKA (Paper II). For the implementation, tables connecting the saturation-
corrected dose-mean specific energy ( ) to particle type and particle kinetic 
energy were generated. The FLUKA implementation was then used to study the 
sensitivity of the MKM to variations in the model parameters (Paper III). The 
created   tables agreed well with the tables applied clinically in Japan. The 
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relative changes in the biological dose distributions during the sensitivity study 
were less than the percentage change of a model parameter. In addition, varying 
multiple parameters simultaneously had mostly smaller impact on the biological 
dose than varying parameters separately. The MKM implementation enables 
conversion from dose distributions obtained with the local effect model (European 
RBE model) to MKM dose distributions, making direct comparisons to the Japanese 
clinical carbon ion data possible.  
In the final part of the thesis, a biological dose model accounting for hypoxia 
was developed for protons and implemented in FLUKA (Paper IV), as well as in a 
FLUKA based treatment planning tool (Paper V). The hypoxia model estimates the 
biological dose as a function of RBE and oxygen enhancement ratio (OER). The OER 
is a function of the LET and the partial oxygen pressure (pO2), which was estimated 
in patients using [18F]-EF5 PET images. Areas with low pO2 values were observed in 
the planning target volume of a head and neck cancer patient, resulting in volumes 
of lower biological dose than prescribed. Treatment plans optimized with the 
hypoxia method had a median biological dose corresponded with the prescription 
dose and physical dose distributions which were increased in the hypoxic areas. 
The optimization of treatment plans with the hypoxic model showed good 
potential for including the OER, as well as the RBE, in treatment planning. 
Overall, this thesis has contributed to knowledge on the RBE and biological 
dose calculations in proton and carbon ion therapy. Monte Carlo studies of an 
experimental or clinical proton or carbon ion beam may help reducing the 
uncertainties in the RBE and biological dose. Given the increase in proton and 
carbon ion facilities worldwide, improving the accuracy of RBE calculations to give 
patients the best possible treatment is more relevant than ever.   
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1. Introduction 
Cancer is a group of diseases caused by uncontrolled division of abnormal cells in 
parts of the body. While diagnostics and treatment modalities for cancer have 
improved greatly the last century with substantially increased survival rates 
(Quaresma et al 2015), cancer is still the second leading cause of death worldwide 
(WHO 2018). Methods for treating cancer are therefore still in continuous 
development, and these include radiotherapy, which has a vital role in cancer 
treatment. The aim of radiotherapy is to kill the cancer cells while sparing the 
healthy tissue. In conventional radiotherapy, the patients are treated with photons 
or electrons. However, due to the physical properties of particles like protons and 
heavier ions, it can be advantageous to use these in radiotherapy (Durante et al 
2017). Radiotherapy with protons and heavier ions is called particle therapy, and is 
currently under planning in Norway, with two proton therapy centers expected to 
open in Oslo and Bergen before 2025.  
Radiotherapy dates back to the end of the 19th century, with three 
fundamental discoveries; the discovery of x-rays by Wilhelm Röntgen in 1895 
(Röntgen 1896), followed by the discovery of natural radioactivity by Henri 
Becquerel in 1896 (Becquerel 1896) and the discovery of polonium and radium by 
Marie and Pierre Curie in 1898 (Curie 1950). The use of x-rays in cancer treatment 
was suggested shortly after Röntgen’s discovery, and already in 1896 x-rays were 
applied in patient treatment (Lederman 1981). In 1904, Wilhelm Henry Bragg 
studied α-particles emitted by radium, and discovered that the α-particles ionize 
most efficient towards the range of the particle (Bragg and Kleeman 1904). This 
ionization peak is now called the Bragg peak, and Robert R. Wilson suggested in 
1946 that this effect could be used in cancer treatment applying protons and 
heavier ions (Wilson 1946). 
Particle therapy has evolved drastically since being suggested by Wilson, 
from being only offered in research facilities to state-of-the-art treatment facilities 
at hospitals. Initially, several particle types, including helium, carbon, neon and 
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argon ions, were used in patient treatment (Castro et al 1980). Today, only protons 
and carbon ions are applied clinically, however, helium ions are about to make a 
comeback, with Heidelberg preparing to start treatments with helium in 2020 
(RaySearch 2019). There are currently more than eighty proton therapy facilities 
worldwide, found in Europe, Asia, North America and South Africa, while carbon 
ion therapy is currently offered in thirteen facilities, in Japan, Europe and China 
(PTCOG 2019).  
Protons and heavier ions have, as mentioned, physical properties which 
makes it possible to better confine the dose to the target when compared to 
conventional radiotherapy. Another difference is that protons and heavier ions also 
have an increased relative biological effectiveness (RBE) compared to photons. In 
particle therapy, an RBE-weighted dose (biological dose) is therefore applied in 
treatment planning. A large amount of data has demonstrated that the RBE varies 
with parameters such as physical dose, biological endpoint, the linear energy 
transfer (LET) and tissue type (Paganetti 2014). Still, a constant RBE of 1.1 is 
currently applied at clinical proton centers, as recommended by ICRU (ICRU 2007), 
ignoring these RBE dependencies. For heavier ions the variations in RBE are too 
large to be ignored. Therefore, clinical carbon therapy facilities generally apply 
variable RBE models, with the local effect model (LEM) in Europe (Scholz and 
Elsässer 2007) and the modified microdosimetric kinetic model (MKM) in Japan 
(Inaniwa et al 2015).  
Monte Carlo codes are useful tools in dose calculations, and regarding the 
dosimetric accuracy, general purpose Monte Carlo codes are considered the gold 
standard (Kozłowska et al 2019). In this thesis, the FLUKA Monte Carlo code 
(Böhlen et al 2014, Ferrari et al 2005) has been used to study the biological dose in 
particle therapy, first as a tool to improve in vitro data for RBE calculations, second 
for comparing and studying a clinically applied biological dose model and last to 
develop and study a new biological dose calculation method which accounts for 
both the traditional RBE dependencies and the tumor oxygen levels in a patient. 
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2. Physics of Particle Therapy 
Radiotherapy utilizes ionizing radiation in treatment of cancer, which is radiation 
with enough energy to detach electrons from atoms or molecules. The goal of 
radiotherapy is to damage the cancer cell DNA enough to kill the cells, while at the 
same time sparing the surrounding healthy cells. The DNA is damaged either by 
direct action, which happens when the radiation has enough energy to directly 
break parts of the DNA, or indirect action, which is when the radiation creates free 
radicals which may be harmful for the DNA (Joiner and van der Kogel 2009). The 
energy deposited in matter by the radiation per unit mass is called the radiation 
dose, and the aim is to deposit enough dose in the tumor to kill it.  
2.1 Interaction of particles with matter 
In particle therapy, the protons or heavier ions interact with the matter mainly 
through inelastic Coulomb scattering, elastic Coulomb scattering and non-elastic 
nuclear reactions, illustrated in Figure 2.1. Through these interactions the particles 
will lose energy, be deflected or removed from the original particle trajectory, 
ionize atoms and create secondary particles.  
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2.1.1 Stopping power 
In inelastic Coulomb scattering, the incoming particle interacts with an atomic 
electron. The electron will be freed from the atom, while the primary proton or 
carbon ion, which is significantly heavier than the electron, will continue in an 
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approximately straight line, however, with a slightly lower energy (Newhauser and 
Zhang 2015). The energy loss rate is generally called the stopping power of the 
particles, and is described by the Bethe-Bloch equation, here as given in Leo (2012):  
	 
   

   
!"#$%
& '  (  )  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Here, , is the mean energy loss over distance -,   is Avogadro’s number,   is the 
classical electron radius,   is the electron mass,  is the speed of light in vacuum, 
 is the density of the absorbing material, . and / are the atomic number and 
atomic weight of the absorbing material, respectively,  is the projectile charge, ( 
is the projectile velocity relative to the speed of light, 0 
 12  (345, 6 is the 
projectile velocity, 789: is the maximum energy transfer in a single collision, ; is 
the mean excitation potential and ) and < are correction terms. 
The particle stopping power is proportional to the square of the charge and 
inversely proportional to the square of the velocity of the primary proton or carbon 
ion (Equation (2.1)). The stopping power will therefore increase with decreasing 
velocity, and the energy loss is therefore highest when the particle has almost 
stopped, leading to the characteristic Bragg peak in the depth dose distribution. As 
carbon ions are heavier than protons, carbon ion therapy requires a higher energy 
to produce the same stopping power as protons, as seen in Figure 2.2. 
 
Figure 2.2: Stopping power in water as a function of energy for protons and carbon ions (a), 
together with depth dose profiles of a 135 MeV proton and a 254 MeV/u carbon ion beam in water 
(b). Stopping power data from ICRU49+73, obtained using the generic stopping power library 




The particle range is defined as the depth at which half of the primary particles 
have come to rest (Newhauser and Zhang 2015). This is an average quantity, due to 
variations in the energy loss of the individual particles called range straggling. The 
range of particles can be calculated according to the continuous slowing down 
approximation (CSDA), i.e. by integrating the particle stopping power from zero to 
the initial particle energy (Fano 1953). Several stopping power and range tables 
have also been made, which makes easy to directly get the range of particles in a 
given medium (Lühr et al 2012). 
Range straggling broadens the Bragg peak of the beam. The ratio of the 
straggling width and the mean range is proportional to 2 =>? , where > is the 
particle mass (Schardt et al 2010). Carbon ions will therefore have a much smaller 
straggling width compared to protons when they have the same range. This 
explains the much sharper Bragg peak of carbon ions compared to protons, seen in 
Figure 2.2b. When irradiating a patient, however, the profile of the Bragg peaks will 
be even broader, due to for instance the density homogeneities of the penetrated 
tissue (Schardt et al 2010). 
2.1.3 Lateral dose profile  
The width of a particle beam traveling through a medium will be broadened due to 
particles passing close enough to nuclei to be elastically scattered or deflected by 
the positive charge of the nuclei (Newhauser and Zhang 2015). While the angular 
deflection of a single scattering can be negligible, the sum of the scattering can 
result in a large deflection from the original path. This effect is therefore called 
multiple Coulomb scattering, and results in an observable lateral broadening of the 
beam with a nearly Gaussian distribution. The lateral broadening is more than 
three times larger for a proton beam than for a carbon ion beam at the same 
range, which is a clinical disadvantage for protons (Weber and Kraft 2009). This 
broadening may be slightly reduced by reducing the air gap between patient and 
beam exit window (Weber and Kraft 2009). By comparison, photons will often have 
a lateral broadening between protons and carbon ions (Rath and Sahoo 2016). 
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2.1.4 Production of secondaries 
In non-elastic nuclear reactions, the primary particle will interact with an atomic 
nucleus, leading to a reduction in the primary particle fluence and the production 
of secondary particles. For this to happen, the primary particles must have enough 
energy to overcome the Coulomb barrier of the nucleus (Newhauser and Zhang 
2015). In proton therapy, the most common secondary particles are secondary 
protons and neutrons. Secondary protons may deposit as much as 10% of the 
absorbed dose in a high-energy proton treatment beam, while neutrons are 
extremely penetrating and have an RBE of as much as 20 times higher than the 
proton RBE, potentially leading to an increased risk of radiogenic late effects 
(Newhauser and Zhang 2015). In carbon ion therapy, secondary ions with lower 
atomic number than carbon may be produced, as well as neutrons and target 
fragments. The secondary ions with lower atomic number than carbon ions have 
longer range than the primary particles (at the same velocity), leading to a 
fragmentation tail after the Bragg peak (Gunzert-Marx et al 2008). This 
fragmentation tail leads to a dose deposition after the Bragg peak of the carbon 
ions, as observed in Figure 2.2b.  
2.2 Physical dose and depth dose curves 
2.2.1 Absorbed dose 
The absorbed dose (physical dose) is a physical quantity describing the mean 
energy imparted by ionizing radiation to matter (ICRU 2011). The unit of absorbed 
dose is gray (Gy), where 1 Gy = 1 J/kg. In conventional radiotherapy, the absorbed 
dose is the standard when reporting the delivered dose to a patient, while in 
particle therapy this dose will be modified to account for biological effects also, as 
described further in Chapter 3.  
2.2.2 Spread-out Bragg peak 
In a clinical scenario, the particle beam must cover an extended area, which is not 
possible with a monoenergetic beam. This leads to the spread-out Bragg peak 
(SOBP), where particle beams with different energies form a uniform dose to the 
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target area (Figure 2.3). This energy modulation is achieved by either introducing 
appropriate filters in the beamline or by tuning the accelerator to deliver beams 
with different energies. While this will give radiation dose outside the tumor area, 
it is still favorable compared to the depth dose curve of conventional radiotherapy 
with photons.  
 
Figure 2.3: Comparison of photon and proton depth dose distributions. The figure is adapted from 
Filipak (2012). 
2.3 Linear energy transfer 
Linear energy transfer (LET) is a measure of a charged particle’s ionization density, 
and is defined as follows:  
@ABC 
 CD , (2.2) 
where E,C is the mean energy lost by the charged particles due to electronic 
interactions when traversing the distance EF, when excluding the transfer to 
electrons with energies above a maximum transfer energy C (ICRU 2011). LETΔ is 
generally called the restricted LET, and it excludes secondary electrons (delta rays) 
with energies above C, as these electrons could deposit their energy relatively far 
from the origin. If all transferred energy is included in the calculation of the LET, the 
quantity is called the unrestricted LET (LETG) and equals the electronic stopping 
power of the particle. In the clinical energy range for protons and carbon ions, it 
can be assumed that there is little difference between LETΔ and LETG (Grzanka 
8 
2014). The unrestricted LET can, in infinitely small volumes, be related to the 
absorbed dose H as follows: 
H 
 IJ @AB, (2.3) 
where K is the particle fluence and  is the tissue density (Gottschalk 2016). This 
shows that fewer high-LET particles are needed to give the same absorbed dose as 
low-LET particles. 
At a given position along the beam, there may be several particles with 
different energies, resulting in several LET values, i.e. an LET spectrum. However, a 
single LET value is often easier to work with, and the LET is therefore commonly 
averaged into for instance dose-averaged LET (LETd). From Equation (2.3), the LETd 
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where D is the absorbed dose contributed by charged particles with kinetic energy 
, at location  and K is the particle fluence. A clinical proton beam will typically 
have LETd values less than 10 keV/μm, while clinical carbon ion beam can have LETd 
values up to 200-300 keV/μm (Kantemiris et al 2011).  
2.4 Microdosimetry 
While the absorbed dose and LET are often applied when determining the damage 
done by the radiation, they may not always be sufficient to describe the 
effectiveness of the radiation (Liamsuwan et al 2014). For better describing this, 
more complete information of energy depositions at the subcellular level can be 
required. Microscopic quantities like the lineal energy and specific energy may 
therefore be useful here. The LET and absorbed dose differ from microdosimetric 
quantities as they quantify the average energy loss of charged particles per 
distance or volume, while the stochastic energy deposition in micrometric volumes 
is measured in microdosimetry (ICRU 1983). 
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2.4.1 Specific energy and lineal energy 
The specific energy () and lineal energy (U) are microdosimetric quantities 
corresponding to the absorbed dose and the LET. The specific energy is defined as 
the quotient of the energy, V, imparted by ionizing radiation in a volume of mass , 
while the lineal energy is the quotient of the energy, VW, imparted to the matter in a 
given volume with a mean chord length of F X by a single energy-deposition event: 
 
 YZ, (2.5) 
U 
 [\DX ] (2.6) 
The specific energy has unit Gy, while the lineal energy has unit keV/μm. The lineal 
energy can be measured directly, and the specific energy can be directly calculated 
from this. While the gold standard of microdosimetric measurements is tissue 
equivalent proportional counters, silicon-on-insulator microdosimeters have been 
developed as an alternative, which increases the spatial resolution significantly 
(Rosenfeld 2016). However, it can be more practical to estimate the specific energy 
using track structure models, which can give the specific energy to a volume as a 
function of the distance from the ion trajectory to the center of the volume 
(Inaniwa et al 2010). 
2.4.2 Track structure models 
When protons or heavier ions ionize atoms, the secondary electrons will generally 
move a distance of a few nanometers to a few millimeters from the particle 
trajectory and deposit dose. To describe the radial dose distribution from ion 
trajectories, track structure models may be used. In carbon ion therapy, the Kiefer-
Chatterjee track structure model (Chatterjee and Schaefer 1976, Kiefer and 
Straaten 1986) and a track structure model by Scholz & Kraft (1996) is applied in 
biological dose calculations in Japan and Europe, respectively. These models 
estimate similar dose distributions from individual tracks, except close to the 
center of the track, as observed in Figure 2.4. 
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Figure 2.4: Track structure for 43 MeV/u carbon ions with LET = 50 keV/μm calculated by the 
Kiefer-Chatterjee model and the model by Scholz and Kraft. The figure is reproduced from Kase et 
al (2008) with permission from IOP Publishing.   
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3. Radiobiology 
When irradiating a biological system, a succession of processes will happen. A time 
after the physical processes have taken place, the biological phase will start. This 
will happen from seconds to years after irradiation, depending on the type and 
severity of the damages (Joiner and van der Kogel 2009). In the biological phase, 
measurable changes to the organism can be seen. While the majority of lesions 
from the radiation are successfully repaired in this phase, some will fail to do this 
and this may eventually lead to mutation or cell death (Joiner and van der Kogel 
2009). The biological effects resulting from irradiation with protons and heavier 
ions will be enhanced compared to irradiation with photons. In the following, the 
linear quadratic (LQ) model, which quantifies the radiosensitivity of cells, and the 
RBE will be described. This will be followed by a description of tumor hypoxia, 
which is a situation where the tumor has areas with low oxygen levels, resulting in 
lower cell radiosensitivity. 
3.1 Linear quadratic model  
The most common way of describing cell survival after irradiation is by the LQ 
model. In this model, the cell survival fraction S is given by   
 1^3 
 _H ` (HN  (3.1) 
where H is the physical dose and _ and ( are radiosensitivity parameters. The _ 
and ( parameters are generally found by fit to experimental data, and the _ (? -
ratio is commonly used to describe the fractionation sensitivity of the cells. 
Studies of tissue responses to radiation have shown that tumors and early 
responding tissues (e.g. skin, oral mucosa and bone marrow) generally have 
1_ (? 3	-ratios (i.e. the _ (? -ratio of photons) in the order of 7-10 Gy, while late 
responding tissues (e.g. heart, lung and kidney) generally have 1_ (? 3	-ratios in the 
order of 3-5 Gy (McMahon 2019). The higher the _ (? -ratio of the cell line, the 
lower the fractionation sensitivity (Leeuwen et al 2018). 
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3.2 Relative biological effectiveness  
The RBE is defined as the ratio of the physical doses of a reference radiation, 
Habcbabdeb, (generally photon radiation) and of the radiation in question,fHg, which 
results in the same biological effect for a given endpoint (IAEA 2008):  
hiA 
 HabcbabdebHg ]f (3.2)  
The biological endpoint can vary; however, for in vitro studies it is often set to 10% 
cell survival, as illustrated in Figure 3.1. From the LQ model (Equation (3.1)) and the 
definition of the RBE, the RBE can be calculated as follows: 
hiA 
 Mj kl mnn'
 ` omMjpMjqn  mnnr, (3.3)  
where Hg is the physical dose of the particles (e.g. proton or carbon ion) and _, (, 
_	 and (	 are the particle and photon radiosensitivity parameters, respectively.  
 
Figure 3.1: Survival fraction curves of V79 cells irradiated with x-rays and 20 keV/μm protons, and 
corresponding RBE calculation at 10% cell survival. Based on data from Belli et al (1998). 
3.2.1 Biological dose 
The prescribed dose in particle therapy is based on the biological dose (also called 
RBE-weighted dose), which is illustrated in Figure 3.2. The biological dose, Hstu is 
calculated as follows: 
Hstu 
 hiA O HgvwWN (3.4) 
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where HgvwW is the total physical dose. Clinically, the RBE in proton therapy is set 
constant and equal to 1.1, ignoring variations in the RBE, while in carbon ion 
therapy the RBE is determined by variable RBE models.  
 
Figure 3.2: Physical dose of a proton spread-out Bragg peak (solid line), with corresponding 
biological dose (dashed line). Here, the RBE was set to 1.1. To distinguish from physical dose, the 
biological dose has the unit Gy(RBE). The depth dose distributions were obtained through FLUKA 
Monte Carlo simulations. 
3.2.2 RBE models 
In order to estimate the variable RBE in particle therapy, several RBE models have 
been developed. These models can generally be divided into two categories. The 
first category is phenomenological models, which considers the particle 
interactions within the cell and the subcellular effects to be a “black box” and 
therefore attempts to estimate biological effects directly by fitting to experimental 
data. The second category is mechanistic/biophysical models, which attempts to 
model the underlaying biological effects on a micrometer scale within the cells. 
Most phenomenological and biophysical RBE models are based on the general RBE 
equation (Equation (3.3)). The difference between the models will be in the 
definition of the radiosensitivity parameters _ and ( of the particles, as well as in 
the values used for the photon radiosensitivity parameters _	 and (	. An extensive 
review of the existing phenomenological RBE models for proton therapy can be 
found in Rørvik et al (2018). In carbon ion therapy, more sophisticated 
phenomenological models or biophysical models are required, due to the “overkill 
effect” at high LET values (Karger and Peschke 2018). Currently in clinical carbon 
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ion therapy, biophysical models are applied in treatment planning, and these are 
described further in Section 4.3. However, a phenomenological model has been 
applied earlier in Japan (Karger and Peschke 2018, Kanai et al 1999). 
3.2.3 RBE dependencies 
Cell experiments have shown that the RBE is dependent on several factors, 
including the biological endpoint, particle type, tissue type, radiation quality and 
the physical dose (Paganetti 2014). In RBE models, the dependency on the 
biological endpoint is generally covered by the experimental data the model is 
fitted to, while the physical dose dependency is covered by the dose input in the 
RBE model (Equation (3.3)). The dependencies on radiation quality, particle type 
and tissue type are covered in the definition of the radiosensitivity parameters, and 
this is where RBE models mainly differ.  
The radiation quality is often quantified by the LET. The RBE will generally 
increase with increasing LET, except at high LET values due to the so-called overkill 
effect, as illustrated in Figure 3.3. This increase in RBE with increasing LET can be 
explained by high-LET radiation having denser track structure than low-LET 
radiation, leading to more severe damage where the track intersects vital 
structures such as the DNA (Joiner and van der Kogel 2009). It is widely accepted 
that the LET amplifies at the distal end of the particle beam, and the RBE will 
therefore generally increase with depth of the beam. The radiation quality can also 
be quantified by the specific energy or lineal energy, and studies have shown that 
these quantities may be more accurate than LET when quantifying the radiation 
quality (Kase et al 2006, Liamsuwan et al 2014). 
The RBE versus LET data in Figure 3.3a show that the RBE is also dependent 
on the particle type. The maximum LET values for protons are much lower than the 
ones for carbon ions, and protons will therefore generally have lower RBE values, 
although protons will generally be more effective than carbon ions for the same 
LET values (Durante and Paganetti 2016). From the data in Figure 3.3b, a 
dependency on cell lines can also be observed. While the general trend between 
the data of these cell lines are similar, the magnitude of the RBE differs. The 
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survival fraction of cells is, as already mentioned, dependent on the tissue type, 
and studies have shown that this is reflected in the RBE, generally with an 
increasing RBE with decreasing cell line 1_ (? 3	-ratio (Schardt et al 2010).  
 
Figure 3.3: RBE as function of LET for different particle types (a) and for different cell lines 
irradiated with carbon ions (b). The figure is adapted from Scholz (2003) with permission from 
Springer. 
3.3 Tumor hypoxia 
Hypoxic cells are cells with low oxygen levels, and these are more radioresistant 
than normal cells (Fleming et al 2015). This effect is often quantified by the oxygen 
enhancement ratio (OER), which is the ratio of the dose at a given oxygen pressure 
(Hv) to that at a standard oxygen pressure (H), producing the same biological 
effect: 
xAh 
 HvHNf (3.5)  
as illustrated in Figure 3.4a. The OER decreases with increasing LET, and carbon 
ions can therefore be quite efficient against hypoxic cells, compared to protons and 
photons (Figure 3.4b). Hypoxia will therefore in general increase the RBE for carbon 
ions, while protons generally do not have high enough LET to make any significant 
difference in OER compared to photons, except towards the range of the proton 
beam (Wenzl and Wilkens 2011).  
Tumor hypoxia arises when the supply of oxygen from the vasculature is less 
than the oxygen consumption in the tumor tissue (Koch and Evans 2015), and the 
level of hypoxia is frequently quantified by the partial oxygen pressure (pO2). The 
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pO2 values at hypoxic conditions are generally below 8-10 mmHg (Silvoniemi 2018), 
while the normal pO2 in tissues may vary from this and up to almost 160 mmHg. 
While there is currently no perfect method for estimating tumor hypoxia, positron 
emission tomography (PET) imaging is normally the preferred method for detecting 
hypoxia in clinical scenarios (Fleming et al 2015).  
Several methods for overcoming the issue with hypoxia in radiotherapy 
have been proposed. One method is to increase the oxygen levels in the tumor 
before treatment, and with this removing the problem before irradiation. An 
important goal here has been to modify the level of hemoglobin before the start of 
radiotherapy, however, this has not been observed to correct tumor hypoxia 
(Welsh et al 2017, Silvoniemi 2018). Other approaches, including breathing of 
carbogen (mixture of 98% oxygen and 5% carbon dioxide) to increase the tumor 
blood flow, have shown some potential, however, not enough to defend the 
inclusion of these methods in clinical practice (Silvoniemi 2018). Another method is 
to modify the treatment plan to take the oxygen levels into account. This includes 
dose painting, where increased radiation dose is prescribed to hypoxic subvolumes 
of the tumor (Malinen and Søvik 2015), and LET painting, where instead the LET is 
increased in the hypoxic areas in the tumor (Bassler et al 2014). Methods for 
including the OER in biological dose calculations have also been proposed 
(Tinganelli et al 2015, Scifoni et al 2013, Bopp et al 2016, Strigari et al 2018). 
 
Figure 3.4: Survival fractions of aerobic and hypoxic cells irradiated with protons with dose-
averaged LET of 17 keV/μm (a), and OER as a function of LET calculated at 10% cell survival with 
pO2 of 160 mmHg and 0.01 mmHg for aerobic and hypoxic conditions, respectively (b). Figure to 
the left is based on data from Prise et al (1990), while figure to the right is created using OER model 
by Wenzl and Wilkens (2011a).  
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4. Treatment Planning  
In radiotherapy, the goal is to irradiate the tumor with the prescribed dose while 
sparing the surrounding healthy tissue as well as possible. This requires careful 
treatment planning. To plan a treatment, computed tomography (CT) images of the 
patient are acquired, and several volumes are delineated: the gross tumor volume 
(GTV) describing the primary tumor; the clinical target volume (CTV) describing the 
extent of microscopic tumor spread around the GTV; the planning target volume 
(PTV) which adds margins around the CTV to allow for planning or delivery 
uncertainties; and relevant organs at risk (OAR) (Burnet et al 2004). A treatment 
planning system (TPS) is subsequently used to create the treatment plan. Dose 
volume histograms (DVHs) coupled with 2D dose distributions are used to get an 
overview of the dose in different regions of interest and to evaluate and compare 
the treatment plan to the prescribed target dose and dose constraints for the OAR.  
4.1  Treatment planning systems  
4.1.1 Analytical treatment planning systems  
Clinically, fast treatment planning is a requirement, leading to a compromise 
between accuracy and computation time. Clinical dose distributions are therefore 
commonly planned and optimized in fast analytical dose calculation algorithms, 
which generally rely on pencil beam algorithms to calculate the dose (Schuemann 
et al 2015). Advanced treatment planning techniques use inverse treatment 
planning, where a dose is prescribed to the PTV, dose constraints are set to the 
OARs, and the TPS will use this to optimize the treatment plan to the best possible 
biological dose distribution.  
The TPS will use patient information given in a DICOM (Digital Imaging and 
Communications in Medicine) format. The files required to perform treatment 
planning are DICOM CT images, which have anatomical information of the patient, 
and DICOM RT Struct, containing information on the delineated structures. After 
creating a treatment plan, information on this plan will be stored in the DICOM RT 
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Plan file, including (but not limited to) information on the treatment beams, dose 
prescription, patient setup, gantry angles, isocenter position and information on 
range shifters. Information on the dose distribution calculated by the TPS can be 
found in the DICOM RT Dose files and can be used to plot the dose distribution and 
DVHs. 
4.1.2 Monte Carlo based treatment planning tool 
While fast analytical TPSs are required for day-to-day clinical treatment planning, 
they have some limitations, especially in difficult and non-standard treatment 
scenarios, involving for instance tissue heterogeneities or metallic implants 
(Mairani et al 2013). Monte Carlo codes will give more accurate dose calculations, 
and are therefore considered the “gold standard” for dosimetric calculations 
(Kozłowska et al 2019). A second issue with commercial TPSs is that they generally 
do not include any RBE models for protons or only include one RBE model for 
carbon ions, making research impractical. Mairani et al (2013) therefore created a 
Monte Carlo based treatment planning tool, using the FLUKA Monte Carlo code 
(Böhlen et al 2014, Ferrari et al 2005). This tool re-optimizes an initial treatment 
plan, created for instance in a clinical TPS. The re-optimization can be performed 
with any RBE model which follows the general RBE formula given in Equation (3.3) 
in Section 3.2 and which is implemented FLUKA. While this tool works well for 
research, it uses much more computational time than the commercial TPSs and is 
therefore not ideal for clinical use.  
4.2 Recalculation of treatment plans in FLUKA 
Our group at the University of Bergen has an in-house made system based on the 
FLUKA Monte Carlo code for recalculation of intensity modulated proton therapy 
treatment plans applying different RBE models (Fjæra et al 2017). This tool can 
automatically translate the information on the treatment plan from DICOM files to 
files readable by FLUKA. This includes information on the radiation beam (beam 
energies, spot positions, spot sizes, spot weights and beam directions), which 
FLUKA reads through the source user routine, and scripts for translating the CT 
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image into FLUKA geometry and scoring regions. The RBE model used in the 
recalculation is defined in the fluscw (FLUence SCoring Weight) user routine. After 
the simulation, the quantities scored by FLUKA can be converted into a biological 
dose distribution in a DICOM RT Dose format. The tool also includes a script for 
plotting and comparing RT Dose files. 
4.3 Clinically applied RBE models in carbon ion therapy 
The main RBE models in clinical use are the local effect model (LEM) version I in 
Europe and the microdosimetric kinetic model (MKM) in Japan. The main model in 
Japan was previously a model developed by Kanai and co-workers (Kanai et al 
1999), and this model is still applied at some centers (Fossati et al 2018). However, 
less was known about heavy-ion RBE when the Kanai model was developed and it is 
therefore based on several oversimplifications, ignoring for instance RBE 
dependencies on dose (Inaniwa et al 2015). Therefore, when the National Institute 
of Radiological Sciences (NIRS) in Japan changed their beam delivery system in 
2011, the RBE model was changed from the Kanai model to the MKM (Inaniwa et al 
2015). At the startup of carbon ion therapy at the Institute of Modern Physics (IMP) 
in China, a constant RBE of 2.5-3 was applied, however, the limitations of this 
strategy were fully acknowledged, also by the IMP (Fossati et al 2018). The MKM 
and LEM I give very different dose distributions, as seen in Figure 4.1. Therefore, to 
transfer clinical protocols between Europe and Japan, conversion factors must be 
applied, as done at Centro Nazionale di Adroterapia Oncologica (CNAO) in Italy 
(Molinelli et al 2016). 
 
Figure 4.1: Biological dose in water as computed by the MKM (NIRS approach, blue), the LEM I 
(chordoma, green) and LEM IV (chordoma, red). The corresponding physical dose (black) is also 
shown. The depth dose distributions were obtained through FLUKA Monte Carlo simulations. 
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4.3.1 Microdosimetric kinetic model  
The MKM predicts the cell survival response after ion irradiation from the specific 
energy deposited in a subcellular structure referred to as the ‘domain’. The model 
also includes a saturation correction for expressing the decrease of RBE due to the 
overkill effect in high specific energy regions (Kase et al 2006). Therefore, when 
applying the MKM, the main parameter to estimate is the saturation-corrected 
dose-mean specific energy of the domain delivered in a single event ( ) (Kase et 
al 2006).  
The MKM applied in Japan is slightly modified from the general MKM. This 
model was introduced clinically at NIRS in Japan in 2011, simultaneously with the 
introduction of a new beam delivery method (Inaniwa et al 2015). At this point, the 
Japanese had almost 20 years of experience with carbon ion therapy, and they 
wanted to continue utilizing this experience. The reference radiation was therefore 
selected to be the center of a carbon ion SOBP with a width of 60 mm and energy 
of 350 MeV/u, assumed to be representative of clinical experience with carbon ion 
therapy at NIRS (Inaniwa et al 2015). Also, a scaling factor was introduced to the 
MKM, to make it possible to continue to use clinical protocols from the original 
system based on the Kanai model (Inaniwa et al 2015, Kanai et al 1999), as 
illustrated in Figure 4.2. In the Kanai model, the dose distribution is rescaled to 
utilize the clinical experience gained with fast neutron therapy at NIRS .  
 
Figure 4.2: Dose planning of a 350 MeV/u carbon ion beam applying Japanese clinical dose systems: 
The original system applying the Kanai model (a) and updated system applying the MKM model (b). 
The figure is reprinted from Inaniwa et al (2015) with permission from IOP Publishing. 
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4.3.2 Local effect model  
The LEM was developed and implemented for treatment planning within the 
carbon ion pilot project performed at GSI, Germany (Krämer and Scholz 2000), and 
is now applied in all European carbon ion therapy facilities. The LEM has been 
further developed since the first version, and the newest version is currently the 
LEM IV. However, only the first version has yet been applied clinically (Solov’yov 
2017). The LEM I and IV varies significantly, as illustrated in Figure 4.1, and as the 
LEM I is the model applied clinically, further explanations of the LEM refers to the 
LEM I. 
The LEM is based on the concept of ‘local dose’, defined as the expectation 
value of the energy deposition at any position in the radiation field for a given 
pattern of particle trajectories (Friedrich et al 2013a). The biological damage in a 
small subvolume of the cell nucleus is, in the LEM, solely determined by the local 
dose in that subvolume, independent of the particular radiation type leading to 
that local dose (Scholz and Elsässer 2007). While this is similar to the approach in 
the MKM, it is in the LEM applied to much smaller volumes (Scholz and Elsässer 
2007). To calculate the local dose from the particles in the LEM, the radial dose 
distribution, estimated by a track structure model from Scholz & Kraft (1996), is 




5. Thesis Objective 
The overall goal of this project has been to contribute to the work of improving 
biological dose calculations in proton and carbon ion therapy. Increasing the 
accuracy of the biological dose calculations in clinical particle therapy may 
significantly improve treatments and working toward this goal is therefore 
important for the treatment outcome of patients. The work in this thesis involved 
performing Monte Carlo simulations to achieve more accurate in vitro RBE data, to 
study an existing clinical RBE model and to develop new methods for biological 
dose calculations in particle therapy. The specific objectives of each of the papers 
are described in the following. 
Paper I:  
 To implement and benchmark the low-energy proton beam cell irradiation 
experiment at the Oslo Cyclotron Laboratory in the FLUKA Monte Carlo code 
 To estimate LETd and LET spectra in the cell irradiation positions properly, using 
the FLUKA implementation 
Paper II and III:  
 To implement the biological dose model applied clinically in carbon ion therapy 
in Japan (the MKM) in FLUKA (Paper II) 
 To use the FLUKA implementation to study the sensitivity of the MKM with 
respect to uncertainties in model parameters (Paper III) 
Paper IV and V:  
 To develop a method which includes patient oxygen levels acquired from [18F]-
EF5 PET images in proton biological dose calculations (Paper IV) 
 To implement this biological dose calculation method in FLUKA (Paper IV) and in 
the FLUKA based treatment planning tool (Paper V) 
 To study the effect of hypoxia on the proton biological dose distribution (Paper 





6. Materials and Methods 
6.1 Implementation of a cell irradiation setup in FLUKA 
The Oslo Cyclotron Laboratory (OCL) has an MC-35 cyclotron (Scanditronix, Lund, 
Sweden), which was used in a cell irradiation experiment. The setup of this 
experiment (illustrated in Figure 6.1) was implemented in the FLUKA Monte Carlo 
code (Paper I), in order to estimate the dose, LET spectra and LETd in the cell 
irradiation positions. The setup geometry was first implemented in FLUKA, and 
then the initial beam parameters (beam energy, energy spread and lateral shape of 
the beam) were determined. The beam parameters were determined by comparing 
Monte Carlo simulated dose with dose measurements acquired using an Advanced 
Markus ionization chamber and Gafchromic (EBT3) dosimetry films at the three cell 
irradiation positions. 
After implementation, the Monte Carlo simulations were used to estimate 
spatial variations in dose and LET in the cell irradiation positions. Water equivalent 
material was used in the cell positions in the simulations, instead of implementing 
the actual cell compositions. The resulting LET spectra were compared with LET 
spectra from a fictive 80 MeV proton beam (representing a clinical low-energy 
proton beam), at positions with equal LETd values.  
 
Figure 6.1: The cell irradiation setup at the Oslo Cyclotron Laboratory: the cell container (a), 
ionization chamber (b), monitor chamber (c) and beam exit window (tungsten) (d). During cell 
irradiation the ionization chamber is removed and replaced by the cell container.  
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6.1.1 LET calculations  
 The LET spectra were estimated at selected depths in the cell irradiation positions 
using the USRYIELD scoring card in FLUKA. This was done by dividing the cell 
irradiation positions into several regions and defining the scoring depths at the 
boundary crossings between two and two regions. The LET was estimated for 
protons (both primary and secondary) only.  
The LETd for protons was estimated in FLUKA using the fluscw user routine. 
This user routine multiplies the particle fluence (K) by a user defined quantity. The 
LET was estimated in fluscw using the internal FLUKA function GETLET(), and from 
this, the quantities @AB y K and @AB y K were scored in each scoring voxel. As 
the LETd for protons was estimated, K is the proton fluence. The LETd in each voxel 
was then found by dividing these two scored values, following the method 
described in Section 2.3.  
6.2 Study of the microdosimetric kinetic model  
The biological dose model applied at NIRS in Japan (the MKM) was implemented in 
FLUKA (Paper II) by defining the radiosensitivity parameters _ and ( in the fluscw 
user routine. This makes it possible to score _ y @AB y K, z( y @AB y K and 
@AB y K in FLUKA, where K is the particle fluence and @AB y K is the dose to 
water (see Equation (2.3) in Section 2.3). From this, the RBE was calculated as in 
Equation (3.3) in Section 3.2. In the MKM, ( is a constant, while _ is a function of 
the saturation-corrected dose-mean specific energy of the domain delivered in a 
single event (M ), which cannot be estimated directly in FLUKA. Tables connecting 
the particle energy to M fwere therefore created, and a method for reading these 
tables was implemented in the fluscw user routine. To quantify the agreement 
between the FLUKA implementation and the NIRS TPS, comparisons were done 
between our specific energy calculations and biological dose estimates and 
corresponding calculations from Japan.  
The sensitivity of the MKM to uncertainties in model parameters was then 
studied (Paper III). The MKM input parameters are the domain radius, { , the 
nucleus radius, |{N and the radiosensitivity parameters _	 and (, and the values of 
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these parameters applied clinically are based on human salivary gland tumor (HSG) 
cells. The sensitivity study was done by varying the model parameters by 
}~N N , as well as comparing the HSG parameter set with parameter sets 
estimated using V79, CHO and T1 cells. Each time either {N |{  or ( was changed, 
new specific energy tables had to be generated for FLUKA. The impact of the 
variations was studied on spread-out Bragg peak scenarios in water, and on a clivus 
chordoma patient.  
6.2.1 Estimating the saturation-corrected dose-mean specific energy  
When creating tables for estimating M , the first step is to calculate the specific 
energy, . This is the energy imparted to the domain divided by the mass of the 
domain, and was estimated based on the same method and assumptions as in 
Inaniwa et al (2010): the domain is assumed to be a cylindrical volume; the 
trajectories of the incident ions are parallel to the cylindrical axis of the domain; 
changes in ion trajectory and speed during the passage of the domain can be 
neglected; the ions constantly generate dose-track structures specific to the ion 
type and energy; and the whole target is composed of water. The specific energy to 
the domain from an ion was estimated using the Kiefer-Chatterjee (KC) track 
structure model (Section 2.4.2). The KC model gives the local dose as a function of 
track radius , ion type (given by the effective charge of the ion,f), particle 
energy , and LET. This dose will in the following be referred to as 
H*oN N ,N @ABq, see Paper III for the entire function. 
When an ion has an impact parameter -, i.e. a trajectory in the distance - 
from the center of the domain, there are three possible scenarios for a given 
distance (t  C) from the track which describes the volume of the domain 
receiving dose, as illustrated in Figure 6.2. The specific energy to the domain for 
this impact parameter will then be the sum of the dose contributions to the domain 
from each given distance from the ion trajectory multiplied by the volume receiving 
this dose, divided by the total volume of the domain: 
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o-N N ,N @ABq 
  MoN4CNNPQRqOC1NCN	3  

 MoN4CNNPQRqOC1NCN	3  . 
(6.1) 
Here, | is the length of the domain, C1tN CN -3 and C/1tN CN -3 are, 
respectively, the volume and area of the domain receiving dose H*oN t 

CN ,N @ABq, {  is the domain radius, C is the step size between the different 
distances from the trajectory and  is the number of steps applied in the 
calculation. The relationship between energy and LET for each particle was found 
from stopping power tables. To calculate C/1tN CN -3, the three cases illustrated in 
Figure 6.2 must be considered.  
In case I, t ` -  { , and here the area of the domain which receives dose 
H*oN t  CN ,N @ABq is the area of a circle with radius t  minus the area of a 
circle with radius t  C: 
C/1tN C3 
  O ot  1t  C3q. (6.2) 
In case II, t ` -  {  and t ` {  -, and here, the area equals the area of 
interception between two circles with radius t  and {  minus the area of 
interception between two circles with radius 1t  C3 and { . The area of 
interception between two circles can be calculated using the following: 
/1|N |N -3 




z1- ` | ` |31- ` |  |31-  | ` |31- ` | ` |3, 
(6.3)
where | and | are the radii of the two circles, and - is the impact parameter 
(Weisstein 2003). In case III, -  { ` t , and therefore larger than the maximum 
impact parameter where the ions can still give an energy deposition to the domain. 
In this case, no dose is given to the domain. 
In the MKM version described in Kase et al (2006) and applied clinically at 
NIRS, the   is given by 
 
 f L $13
ST
L 13ST . (6.4) 
Here, 13 is the probability density of  deposited by a single energy-deposition 
event of the domain and W  represents the saturation-corrected specific energy. 
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When mono-energetic ion irradiation is considered, W  and  can be described as 
a function of the impact parameter. In this case it was shown by Inaniwa et al 
(2010) that  , for a given ion charge, LET and energy, can be generated using the 
following: 
 
 f L $1	31	3O		
ZT
L 1	3O		ZT
  $1	31	3O	C	  1	3O	C	 , (6.5) 
where C- is the size of the impact parameter steps used in the summation and   
is the maximum impact parameter where the ions can still give an energy 
deposition to the domain. The function ¡9¢1-3 is given in Appendix A in Paper III, 
and is a function of 1-3 and three constants: the domain radius ({), the nucleus 
radius (|£), and the radiosensitivity parameter (]  
 
Figure 6.2: The three scenarios to account for when calculating the specific energy given by an ion 
to the domain with radius rd given impact parameter - the domain will receive all dose given 
by the ion for this track radius r (case I), the domain will only receive part of dose from the ion 
(case II) and the domain will not receive any dose (case III). The part colored in red illustrates the 
area which receives a given dose. 
6.2.2 Recalculation of carbon ion treatment plans 
The carbon ion treatment plans applied in Paper II and III were originally optimized 
with commercial TPSs and then recalculated with different biological dose models 
in FLUKA. The commercial TPSs were either the NIRS TPS (applying the Kanai 
model) or the Syngo (VC11B, Siemens AG, Erlangen, Germany) TPS at CNAO 
(applying the LEM I). The treatment plans were recalculated using CNAO’s in-
house-made scripts for converting CT information and beam information from the 
original treatment plan to a format readable by FLUKA. 
Treatment plans originally optimized with the Kanai model were 
reoptimized with the MKM in FLUKA to test the FLUKA implementation of the 
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MKM. While the Kanai model and the MKM differs, they both provide uniform 
clinical dose distributions to the targets, consistent with the dose prescription 
(Inaniwa et al 2015). These treatment plans were passively delivered plans, 
requiring the beam in FLUKA to be properly collimated on the patient’s tumor and 
modulated by ridge filters to be equivalent to the plan delivered at NIRS.  
Treatment plans originally optimized at CNAO were recalculated in FLUKA 
using an implementation (created at CNAO) of the CNAO beamline geometry in 
FLUKA (illustrated in Figure 6.3). In the FLUKA implementation of the CNAO 
beamline, the beamline is fixed, and when simulating a patient irradiated from 
multiple angles, the patient geometry (Figure 6.3d) is rotated and not the 
beamline.  
 
Figure 6.3: Illustration of the CNAO beamline in FLUKA, from the geometry editor in FLUKA’s 
graphical user interface (flair): vacuum pipe (a), the two beam monitoring chambers (b), air (c) and 
patient structure obtained from a CT DICOM image (e). 
6.3 A biological dose method accounting for hypoxia 
To include cell oxygen levels, as well as the RBE, in biological dose calculations, a 
biological dose method based on the RBE and the OER was developed (Paper IV). 
The method applies an existing variable RBE model which is based on the LQ model 
(see Equation (3.3) in Section 3.2), and adapts the model to hypoxia by modifying 
the aerobic radiosensitivity parameters of the particles, _ and (, to be functions 
of the OER: 
_v 
 m¤¥Q¦1§Ng3, (6.6) 
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z(v 
 z¤¥Q¦1§Ng3, (6.7) 
where ¨ is the LETd and © is the pO2. The OER given by the following:  
xAh1¨N ©v3 
 zm1§Ngª34«1gª3 O¬d1­34m1§Ngª3zm1§Ng¤34«1g¤3 O¬d1­34m1§Ng¤3 O
1g¤3
1gª3, (6.8) 
with _1¨N ©3 and (1©3 defined as: 
_1¨N ©3 
 1pO§3Ogp1®p¯O§3Ogp ,  (6.9) 
z(1©3 
 sOgpsOgp ]  (6.10) 
Here, K is a parameter which controls the rate of change in OER with pO2 and is set 
to 3 mmHg and a1, a2, a3, a4, b1 and b2 are model parameters found by fit of in vitro 
data. The OER model was based on Wenzl & Wilkens (2011), however, with the 
model parameters modified to proton in vitro data only.  
The method was implemented in FLUKA (Paper IV) and in the FLUKA based 
treatment planning tool (Paper V). To demonstrate model performance, SOBPs in 
water phantoms with pO2 varying for strongly hypoxic (0.01 mmHg) to aerobic (30 
mmHg) was applied in Paper IV, while a SOBP scenario in a water phantom with 
pO2 varying with depth was applied in Paper V. The method was also demonstrated 
(in both Paper IV and V) on a head and neck cancer patient with pO2 levels 
estimated from [18F]-EF5 PET images.  
6.3.1 Recalculating proton plans  
Recalculation of proton treatment plans with the biological dose model accounting 
for hypoxia (Papers IV and V) was based on our in-house made system for 
recalculation of treatment plans in FLUKA, described in Section 4.2. In this system, 
the patient is always kept still, while the beam is rotated around it. The main 
modification of our in-house system was the implementation of the hypoxia 
adapted biological dose calculation method in FLUKA. In addition, the script for 
converting scored quantities into DICOM RT Dose files was modified to both store 
the correct biological dose and the pO2 values in separate files, to enable plotting 
of both the biological dose distribution and of the patient pO2 distribution.  
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The FLUKA implementation was done using the fluscw user routine, as with 
the implementation of the MKM described in Section 6.2. The difference to the 
MKM implementation was the description of the _ and ( parameters. In the 
hypoxia model they are functions of _ and (  (aerobic radiosensitivity 
parameters), which in proton therapy often is functions of the LETd, and of the OER, 
which is a function of pO2 and LETd. The LETd was estimated as described in Section 
6.1.1, while the pO2 values were implemented in FLUKA by tables connecting the 
particle position to pO2, as described in the following.  
6.3.2 Creating pO2 tables 
When creating the pO2 tables for FLUKA, the first step was to estimate the pO2 
corresponding to each PET voxel. The pO2 values were estimated from [18F]-EF5 PET 
images, by creating a conversion curve from PET uptake to pO2, based on PET 
uptake in organs with known pO2 values (described in detail in Appendix A in Paper 
IV). Then, the coordinate system of the PET image was converted to the FLUKA 
coordinate system, based on our in-house made tool for FLUKA based treatment 
plan recalculation (Section 4.2). Here, isocenter of the treatment plan is the origin 
of the coordinate system.  
The pO2 table included information on the voxel size in each direction (C-, 
CU and C), and on the position of each separate voxel and its pO2 value. In the 
fluscw routine, it is possible to obtain information on the particle position 1-N UN 3. 
Therefore, to make the table readable by fluscw, the starting position of each 
separate pO2 voxel was described with its coordinate 1-tN UtN t3] Then, the fluscw 
routine could find the voxel corresponding to the particle position, by using an if-
sentence corresponding to -t  -  -t ` C-, Ut  U  Ut ` CU and t    t `
C. The pO2 value in this voxel was then assigned to the particle at this position.  
6.3.3 Implementation in the FLUKA based treatment planning tool 
The biological dose model accounting for hypoxia was implemented in the FLUKA 
based treatment planning tool, to enable optimization of treatment plans with this 
model (Paper V). The workflow of the FLUKA based treatment planning tool is given 
in Figure 6.4. First, an initial guess of the treatment plan, generally from a 
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commercial TPS, is recalculated in FLUKA, where _H and z(H are scored. Then, 
the optimizer calculates the RBE according to Equation (3.3) in Section 3.2. The 
fluscw user routine from Paper IV was used to score _H and z(H, however, some 
format modifications had to be done as the optimizer runs on the FLUKA 
development version. Prescription dose to PTV and constraints to relevant OARs, as 
well as the photon radiosensitivity parameters, were given in separate files which 
the optimizer reads. The optimization was done using the dose difference 
optimization algorithm described in Mairani et al (2013). 
 
Figure 6.4: Workflow of the procedure for dose optimization with the Monte Carlo based treatment 
planning tool. Adapted from workflow chart by Mairani et al (2013).  
6.4 Ethical considerations 
The patient data applied in this study was provided by CNAO (Paper II and III) and 
Turku University Hospital (Paper IV and V) and was used with permission from 
these facilities. All patient material was anonymized, and the patients from Turku 






7. Summary of Results 
7.1 More accurate knowledge of the LET for cell experiments  
7.1.1 Paper I: LET estimations at cell irradiation positions at the OCL 
In Paper I, the experimental setup for cell irradiation at the Oslo Cyclotron 
Laboratory (OCL) was implemented in the FLUKA Monte Carlo (MC) code. 
Comparisons between FLUKA simulated dose and measured dose data at three 
potential cell irradiation positions showed that the experiment was carried out 
with a 15.5 MeV proton beam. A MC simulated 80 MeV proton beam (representing 
a low-energy proton beam at clinical facilities) was included for comparisons.  
The OCL LETd were found to increase from 4-7 keV/μm at the beam 
entrance to 34-35 keV/μm at the proton range, R80 (Figure 7.1a). This was 
significantly higher than the 80 MeV proton beam LETd, which was less than 15 
keV/μm at the proton range. The LET spectra broadened with beam depth (Figure 
7.1b). However, the OCL LET spectra were still considerably narrower than the 80 
MeV proton beam spectra which resulted in the same LETd values. The setup can 
therefore be used to study the RBE-LET relationship of protons with narrow LET 
spectra and high LETd values. However, as the LETd varies rapidly at these energies, 
accurate dosimetry and MC simulations are essential for reducing uncertainties.  
 
Figure 7.1: Depth dose profile (gray) of the OCL proton beam with corresponding LETd (black) (a) 
and LET spectra (b), estimated at one of the cell irradiation positions. The LET spectra were 
estimated at the beam entrance, E (black), Bragg peak, BP (blue), particle range, R80 (green) and 
center of distal dose fall-off, cddf (red), as illustrated by circles in (a). The figure is reprinted from 
Paper I with permission from Taylor & Francis Group. 
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7.2 Study of a clinical RBE model  
7.2.1 Paper II: Implementation of the MKM in FLUKA 
In Paper II, the RBE model used for carbon ion therapy at NIRS in Japan (the MKM) 
was implemented in FLUKA. The MKM is based on the saturation-corrected dose-
mean specific energy (M ) to small subvolumes of the cell nucleus called domains. 
Calculations of specific energy and M  were in good agreement with the 
calculations applied at NIRS (Figure 7.2). Small differences in the calculated M  
were observed for helium ions at low energies, resulting from the choice of energy 
versus LET input table, as the accuracy of these tables depends on how they are 
estimated. However, the observed differences were shown to not affect 
agreements with experimental data at clinically relevant energies. 
Comparisons between carbon ion biological dose calculations performed 
using the FLUKA implementation and the NIRS TPS showed a satisfactorily 
agreement, with median target RBE deviations of at most 3% for the applied 
patient cases (prostate and pancreas). Larger differences were observed for RBE 
values registered for small portions of the target volume. However, these 
differences were still small enough to be attributed to differences between the MC 
detailed particle transport and the analytical method of the TPS. The 
implementation enables direct comparisons in FLUKA between the biological doses 
estimated using the LEM and the MKM for given treatment scenarios. 
 
Figure 7.2: Comparison between our calculations and calculations from NIRS: the specific energy, , 
as a function of impact parameter (a) and the saturation-corrected dose-mean specific energy, M N 
as a function of kinetic energy for six ion types (hydrogen to carbon). The figure is reprinted from 
Paper II with permission from IOP Publishing. 
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7.2.2 Paper III: Sensitivity study of the MKM model parameters 
A sensitivity study of the MKM was performed in Paper III, to assess potential 
under- or over-dosage of a tumor and surrounding healthy tissue due to errors in 
the model parameters. Variations in the domain radius, { , had the largest impact 
on the biological dose estimations, as seen in Figure 7.3 for a carbon ion SOBP in 
water. This was not surprising, as {  represents the sensitive volume in the MKM, 
and the estimated specific energy is highly dependent on the size of this volume. 
Variations in the nucleus radius, |£, resulted mainly in changes in the biological 
dose toward the particle range. This was because |£ is only used in the saturation 
correction at high specific energy regions, found at the distal end of the beam. 
Variations in the radiosensitivity parameters _	 and ( resulted in small and almost 
reverse changes in the biological dose. Generally, the relative changes in the 
biological dose were less than the percentage change of the parameter. 
The carbon ion SOBP in water was also recalculated applying the MKM with 
input parameters based on V79, T1 and CHO cells. This gave mostly higher 
biological doses than the HSG SOBPs, with a few exceptions at the beam entrance. 
While the parameter sets differed significantly, the combined effect of each 
parameter set resulted in moderate differences across calculated biological doses. 
Also, while an increase in biological dose was observed towards the particle range 
for the V79, T1 and CHO calculated SOBPs, all parameter sets resulted in a flat 
SOBP when two opposing beams were combined. A clinical case (clivus chordoma 
tumor) showed the same dependencies on parameters as the SOBPs in water.  
 
Figure 7.3: Depth dose profiles in water for a 3 Gy(RBE) carbon ion SOBP, optimized with nominal 
HSG parameters and recalculated with HSG parameters increased (a) and decreased (b) separately 
by 25 %, respectively. The figure is reprinted from Paper III with permission from IOP Publishing. 
38 
7.3 Including hypoxia in biological dose calculations  
7.3.1 Paper IV: Development and implementation of a hypoxia model in FLUKA 
A biological dose calculation method which accounts for hypoxia and RBE was 
developed for proton therapy and implemented in FLUKA in Paper IV. The 
biological dose decreased with decreasing pO2 values, similar to the respective OER, 
both when applying an RBE of 1.1 (DRBE1.1) and the variable RBE model by Rørvik et 
al (2017) (DROR). The OER was mostly constant throughout the beam, with a slight 
decrease at high LETd. This decrease was most prominent at low oxygen levels; at 
the most extreme hypoxic condition applied in the study (0.01 mmHg) the OER 
value went from 2.7 at the beam entrance to 2.3 at the distal end of the beam.  
The pO2 values on a voxel-by-voxel basis in a head and neck cancer patient 
were estimated from [18F]-EF5 PET images, showing areas with low pO2 in the PTV. 
At the corresponding locations, the biological dose was lower than the prescribed 
dose, as illustrated in Figure 7.4. The PTV had pO2 values in the range of 2.2 - 60 
mmHg, with mean pO2 of 16.8 mmHg. The resulting median target biological doses 
calculated using DOER,RBE1.1 and DOER,ROR was a factor 1.12 and 1.11 lower than the 
DRBE1.1 and DROR biological doses, respectively. This corresponds well with the OER at 
16.8 mmHg for low-LET radiation. The results show that neglecting the effect of 
hypoxia in proton therapy could potentially compromise the expected tumor 
control probability and should, together with RBE variations, therefore be kept in 
mind in clinical practice. 
 
Figure 7.4: Head and neck cancer patient; pO2 map (a), DOER,RBE1.1 biological dose (b) and dose 
difference between DRBE1.1 and DOER,RBE1.1 biological doses (c). The PTV is delineated in pink. The pO2 
table includes only pO2 values inside and directly around the PTV, while outside the table the pO2 
was set to 60 mmHg. The pO2 in voxels receiving doses below 0.7 Gy(RBE) according to the DRBE1.1 
dose is set transparent.  
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7.3.2 Paper V: Optimization of treatment plans with the hypoxia model 
In Paper V, the hypoxia model from Paper IV was implemented in a FLUKA based 
treatment planning tool. The tool was demonstrated on two proton SOBP scenarios 
(single and opposing fields) in a simulated water phantom and for the head and 
neck cancer patient from Paper IV. The water phantom had pO2 levels varying with 
depth in the beam direction. Optimization of the SOBP scenarios in water resulted 
in similar dose distributions, with a nearly homogeneous biological dose 
distribution to the target (Figure 7.5) in both cases. The corresponding RBE 
distribution (where only the proton dose accounts for hypoxia) were seen to follow 
the oxygen levels almost in a stepwise manner. The RBE in the most hypoxic region 
(2.5 mmHg) was a factor of 1.43 below the RBE of 1.1 at non-hypoxic regions. This 
is close to the OER at 2.5 mmHg for low-LET radiation.  
The patient pO2 was estimated from [18F]-EF5 PET images. The patient plan 
was reoptimized with the hypoxia model, resulting in a median PTV dose of 70.8 
Gy(RBE), agreeing satisfactorily with the prescribed dose of 70 Gy(RBE). However, 
the dose to one of the parotid glands was increased considerably compared to the 
original Eclipse optimized treatment plan which did not account for hypoxia. Still, 
as the contra-lateral parotid gland was almost completely spared, the probability of 
xerostomia (dry mouth) would be small for this case. Taking account of the RBE and 
OER in biological dose optimization can give a more beneficial physical dose 
distribution to the tumor, however, it may lead to violation of normal tissue 
constraints. 
 
Figure 7.5: Biological dose distributions (black) optimized with the Monte Carlo based optimizer 
(MC OPT) using the hypoxia model (solid line) and with the Eclipse TPS using a constant RBE of 1.1 
(dashed line), with corresponding RBE distributions (red). *The MC OPT RBE is not a directly an RBE 





The RBE is currently applied in treatment planning in particle therapy to account 
for the different biological effectiveness across radiation qualities. This makes it 
possible to use treatment protocols from conventional radiotherapy (or from 
earlier clinical experience with particles) in particle therapy. It also makes it 
possible in treatment planning to optimize a homogeneous biological dose to the 
target, as done in clinical carbon ion therapy. The accuracy of the estimated RBE is 
therefore important for the treatment received by particle therapy patients. In this 
thesis, the RBE and biological dose has been studied using the FLUKA Monte Carlo 
code. Initially, a cell irradiation experiment was implemented in FLUKA to enable 
accurate dose and LET estimates in the cell irradiation positions (Paper I). In the 
next project, the RBE model applied clinically in Japan (the MKM) was implemented 
in FLUKA (Paper II), and further investigated through a sensitivity study of the 
model input parameters (Paper III). Finally, a biological dose method which 
accounts for hypoxia and RBE was developed and implemented in FLUKA (Paper IV) 
and in a FLUKA based treatment planning tool Paper V).  
Monte Carlo simulations are useful in particle therapy, as they can provide 
additional and more accurate information on how the radiation interact in tissue 
compared to analytical treatment planning systems. The physics models of FLUKA 
have been shown to reproduce measured depth and lateral dose profiles in water 
well for all clinically interesting ions. They have, in addition, been shown to treat 
the transport and interaction of primary particles and produced fragments 
consistently for protons and ion beams at therapeutic energies (Battistoni et al 
2016). FLUKA is applied at the leading European particle therapy centers CNAO and 
Heidelberg Ion-beam Therapy Center (HIT), both in research and to guide 
treatment planning decisions when needed (Parodi et al 2012, Tessonnier et al 
2014). FLUKA has also been used to support developments of some commercial 
analytical TPSs (Battistoni et al 2016). FLUKA may therefore be a helpful tool when 
we get our first proton centers to Norway in a few years. 
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8.1 Improving RBE measurement data 
While a constant RBE of 1.1 is currently applied clinically in proton therapy, it is 
becoming widely accepted that the proton RBE is variable and that proton therapy 
could benefit from including a variable RBE in treatment planning (Willers et al 
2018). However, the currently existing proton RBE models estimate considerable 
different RBE values, complicating the introduction of variable RBE in clinical 
proton therapy (Rørvik et al 2018). In carbon ion therapy, the RBE varies 
significantly and must be accounted for clinically. However, the clinically applied 
carbon ion RBE models estimate vastly different biological dose distributions for 
the same irradiation scenarios. Better RBE data are therefore required to increase 
the accuracy of the RBE estimates, both for proton and carbon ion therapy. The aim 
of Paper I was to improve in vitro RBE data for protons. This was done by providing 
an accurate description of the dose and (in particular) the LET distribution in a cell 
irradiation experiment, which subsequently has been used in several cell irradiation 
studies (Rykkelid 2017, Baker 2018, Tormodsrud 2019).  
In proton RBE models, the LET is commonly described by the LETd (Rørvik et 
al 2018). While there is currently an abundance of in vitro RBE-LET data which can 
be used for RBE models, the data are associated with large uncertainties (Paganetti 
2014). Most published in vitro RBE experiments do not provide the LETd at the 
measurement points, and when it has been reported it is often roughly estimated 
from stopping power tables, based on the beam energy (Paganetti 2014). To 
ensure accurate LET estimations of the beam, it is therefore important with proper 
implementation of the experimental setup in Monte Carlo codes (Durante et al 
2019). This was also emphasized in an editorial following the publication of Paper I 
(Grassberger and Paganetti 2017), which highlighted how Paper I and similar 
studies are necessary in paving the way for clinically biological treatment 
modelling, by decreasing experimental error by characterizing the incoming beam 
properly. 
In addition to having a proper implementation of the experimental setup, it 
is important to report how the LET values were calculated, as this influences the 
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estimated values. In this thesis, the LETd and LET spectra have been estimated 
based on primary and secondary protons only, which has also been typical in other 
studies (Yepes et al 2019, Granville and Sawakuchi 2015). Grassberger and 
Paganetti (2011) showed that secondary protons have a significant influence on the 
clinical LETd distribution and should therefore be included in biological 
optimization. Including other secondary particles may also have a significant impact 
on the LETd estimation and can even double the LETd value (Grzanka et al 2018). 
Another difference in reported LET values arises from whether the LET to water or 
to tissue is estimated, as these can differ significantly (Wilkens and Oelfke 2004). In 
this thesis, the LET to water was scored, as dose to water is the standard to report 
in radiotherapy (IAEA 2000). The LET can also be scored volumetrically or across the 
boundary of two regions (Guan et al 2015). The LETd was, in this thesis, scored 
volumetrically, in a grid equal to the dose grid, while the LET spectra were scored 
across boundaries. The LETd could also be scored across boundaries, however, this 
method has some limitations when scoring the LETd from irradiation scenarios with 
several beams. 
Most variable RBE models for protons are, as mentioned, based on the LETd. 
However, when comparing the low-energy OCL proton beam with an 80 MeV 
proton beam (Paper I), significantly different LET spectra were observed for the 
same LETd values. Similar results were found by Howard et al (2018), who 
compared a 71 MeV proton beam and a 160 MeV proton beam, and observed clear 
differences in lineal energy spectra for the same dose-averaged lineal energy. Also, 
it can be shown that estimating the RBE from the LETd is only appropriate if the 
relationship between the RBE and LET is linear. This emphasizes the hypothesis in 
Rørvik et al (2017) that proton RBE models based on the LET spectrum may be 
more appropriate than models based on the LETd. Grün et al (2019) further showed 
that the RBE can only be accurately reflected by the LETd for narrow LET 
distributions. If the inaccuracy of using the LETd for expressing the RBE in a mixed 
field is large enough to be clinically relevant, it should be studied further. However, 
only full Monte Carlo software like FLUKA is currently able to produce the full LET 
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spectra of a beam. To implement an RBE model based on the LET spectrum in a 
commercial TPS, an analytical algorithm for the full LET spectrum must therefore be 
created, unless the commercial TPS is MC based. Similar considerations might also 
be relevant in carbon ion therapy, where the RBE is often characterized by the 
frequency or dose mean values of the specific energy (Grün et al 2019).  
While LET is the most widely used quantity describing the radiation quality, 
microdosimetric quantities may be more accurate to use, as these will reflect the 
statistical nature and the spatial patterns of energy depositions in the ion track 
(Liamsuwan et al 2014). Microdosimetric quantities may also, unlike the LET, be 
measured directly in the beam. However, applying microscopic quantities presents 
some challenges. Liamsuwan et al (2014) showed that the dose-averaged lineal 
energy (U) depended to a large degree on the target size, with decreasing U with 
increasing target size. This was also observed in our sensitivity study in Paper III, 
where the radius of the domain had a large impact on the estimated saturation-
corrected dose-mean specific energy.  
RBE models are generally based on in vitro data. However, the 
radiosensitivity of cell lines might not reflect a clinical scenario perfectly. Studies on 
in vivo and clinical RBE should therefore give a more realistic picture of the RBE in a 
clinical beam. However, there are only a limited number of such studies (Sørensen 
et al 2017). To better utilize existing in vivo RBE data, Lühr et al (2017) introduced a 
beam quality factor Q, as an alternative to the LET, to quantify the RBE. By applying 
Q, which is a function of the charge and energy of the ion, in RBE estimates, the 
RBE dependency on ions which exists with the LET can be removed. This makes it 
possible to utilize in vivo data for heavier particles when determining the proton 
RBE.  
A few years ago, there was still no clinical evidence suggesting that the 
proton RBE deviated significantly from the applied value of 1.1 (Paganetti 2015). 
However, several newer in vivo studies have shown that the RBE of 1.1 is most 
likely an underestimation (Sørensen et al 2017, Saager et al 2018). Recent studies 
have also found clinical evidence that support a variable RBE. Peeler et al (2016) 
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showed that changes on post treatment MR images in children treated with proton 
therapy depended on both the physical dose and the LET, and a study on chest-wall 
patients by Underwood et al (2018) supports the hypothesis of a variable clinical 
proton RBE. Eulitz et al (2019) further studied post MR images in four glioma 
patients treated with proton therapy and showed that non-uniform distributions of 
necrotic lesions within the brain were highly correlated with a combination of dose 
and LET.  
8.2 Applying variable RBE models clinically 
Variable RBE models are currently applied clinically in carbon ion therapy, with the 
leading models being the LEM I in Europe and the MKM in Japan. These models 
estimate significantly different RBE values for the same scenarios (see Figure 4.1 in 
Section 4.3), and carbon ion treatment protocols can therefore not be directly 
interchanged between European and Japanese facilities. It is therefore of high 
clinical relevance to have the possibility of making direct comparisons between the 
two models. This was the goal of Paper II, and was achieved by implementing the 
MKM in FLUKA, where the LEM had already been implemented (Mairani et al 
2010). The significant differences between the models also make it relevant to 
assess possible uncertainties in the models, which was conducted in Paper III. 
While the MKM and LEM I estimate significantly different biological dose 
distributions, they are based on some conceptual similarities. In both models the 
main target is the cell nucleus, which is divided into small independent 
subvolumes. Also, the summation of the local effect in these subvolumes 
determines the cell survival probability in both models (Kase et al 2008). However, 
the size of the subvolumes and the dose-effect curves are different between the 
models (Kase et al 2008). The endpoint of the applied clinical models also differs; 
the clinical MKM uses parameters based on HSG cells while the clinical LEM uses a 
general 1_5(3	 of 2 Gy (Fossati et al 2012). The MKM applied at NIRS also uses a 
carbon ion beam as reference radiation, and not photons as used in LEM. 
Japan has the longest clinical experience in carbon ion therapy. While the 
originally applied Kanai model (Kanai et al 1999) included many simplifications, its 
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appropriateness was demonstrated by the observed local tumor control (Inaniwa 
et al 2015). To make use of this experience, CNAO in Italy adapt their clinical 
protocols to Japanese protocols by applying conversion factors (target median dose 
ratios). These factors were estimated by Fossati et al (2012) and later confirmed by 
Molinelli et al (2016), and are computed as median target ratios. While the 
conversion factors are based on the Kanai model, the target dose is the same with 
the Kanai model and the clinically applied MKM model. However, as seen earlier 
(Figure 4.1 in Section 4.3 and Paper II), the difference between the LEM I and the 
MKM or Kanai model is not only a generic scaling difference. Applying scaling 
factors to convert normal tissue constraints between the facilities may therefore be 
a problem. Dale et al (2019) showed that the dose constraints applied for the optic 
nerve at CNAO, based on NIRS constraints, are conservative, and they proposed 
new and safe dose constraints for this OAR. They also stressed the need for 
validation of OAR constraints for both RBE models. Having the FLUKA tool available 
for recalculating treatment plans with both LEM I and MKM (Paper II) is therefore 
useful, as it can provide exact dose distributions for comparisons. 
The LEM has been further developed several times, with LEM IV being the 
newest model version. The main concept of the LEM, i.e. equal local dose should 
result in equal biological effect, is conserved in the LEM IV (Elsässer et al 2010). 
However, in the LEM IV, the biological response is directly related to the double-
strand break pattern (Giovannini et al 2016). The LEM IV has a stronger 
dependence on the LET than the LEM I, and studies suggests that the LEM I is best 
at predicting the RBE at low-LET regions, while the LEM IV is most accurate in high-
LET regions (Karger and Peschke 2018, Saager et al 2018). However, as there are 
currently not enough data to assess whether the LEM I or the LEM IV is best at 
describing clinical scenarios, the LEM I is still applied clinically in Europe (Gillmann 
et al 2019). 
The large differences in the biological dose estimates between the various 
models enhances the importance of assessing the model uncertainties. The 
purpose of Paper III was therefore to study how uncertainties in the MKM input 
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parameters (domain radius, nucleus radius, _	 and () would impact the biological 
dose. This has been done partly for the LEM I (Chanrion et al 2014), and more 
comprehensively for the LEM IV (Böhlen et al 2012, Friedrich et al 2013b). For the 
MKM, however, only less extensive sensitivity studies had been performed 
(Remmes et al 2012, Mairani et al 2017). The sensitivity study in Paper III showed 
that uncertainties in the domain radius resulted in the greatest uncertainties in the 
MKM biological dose, with decreasing biological dose with increasing domain 
radius. Böhlen et al (2012) found for the LEM IV that the largest risk of 
misestimating was expected in the high-LET area inside and close to the PTV. The 
same was observed in Paper III when varying the entire MKM parameter sets. 
Friedrich et al (2013b) found, similar to us, that a change in model parameters (in 
this case the LEM IV parameters) resulted in a smaller percentage change in the 
resulting RBE.  To further reduce uncertainties, Friedrich et al (2013b) suggested 
using for instance biomarkers for a more personalized determination of input 
parameters. 
In proton therapy treatment planning, variable RBE is, as already 
mentioned, not yet implemented clinically. However, there is an awareness of the 
potential RBE issues during treatment, especially the fact that the RBE increases 
with increasing depth in patient. This is currently handled by careful selection of 
field angles, avoiding organs at risk at the distal end of the treatment fields 
(Paganetti et al 2019). However, there is a growing consensus in the scientific 
community that these measures are insufficient, and that incorporation of more 
detailed RBE parameters in proton therapy treatment planning is a necessary step 
to improve the quality of the treatment (Willers et al 2018). Currently at the MD 
Anderson Cancer Center in Texas, USA, the first clinical trial worldwide which 
includes variable RBE in proton therapy treatment planning is initiated (MD 
Anderson Cancer Center 2019). While this clinical trial only includes a relatively 
simple RBE model (LET optimization), it is a step in the direction towards including 
variable RBE in proton therapy. 
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8.3 Including hypoxia in biological dose calculations 
Hypoxia relates to poor treatment prognosis and outcome. This poses a significant 
problem in cancer treatment, as studies show that most types of solid tumors 
contains hypoxic regions of clinical significance (Dhani et al 2015, Evans et al 2009). 
Tumor hypoxia varies on a tumor-to-tumor basis, and the presence and extent of 
hypoxia must therefore be assessed in each patient to optimize the treatment 
(Koch and Evans 2015). Paper IV and V addressed this issue, by first developing a 
biological dose method adapted for hypoxia, and then by creating tools for 
recalculating and optimizing proton treatment plans with this method. The tools 
showed promising results, however, better estimation of the patient pO2 is 
required before applying the method clinically. Also, applying the method on more 
patients will be needed to demonstrate the robustness of the method.  
The feasibility of imaging hypoxia with PET has been clinically demonstrated 
in several cancer types (Kelada and Carlson 2014). Applying imaging modalities like 
PET and magnetic resonance imaging (MRI) for estimating hypoxia is non-invasive 
and feasible in a clinical setting. Several PET hypoxia tracers have already been 
used in completed or ongoing clinical trials on simultaneous dose escalation using a 
dose painting technique in photon therapy (Zhang et al 2016). However, it has been 
shown that the detection of hypoxia is still imperfect, and that the focus on hypoxia 
detection should continue (Bredell et al 2016). In the process of assessing how 
accurate the modalities are at estimating hypoxia, it could be interesting to 
compare different image modalities, like different PET tracers (e.g. [18F]-EF5, [18F]-
FMISO and [18F]-FDG) and different techniques of MRI (e.g. DCE-MR and DSC-MR). 
Detecting hypoxia only prior to treatment may also be insufficient, as the extent of 
hypoxia in the tumor will vary during treatment. However, as the treatment will 
most likely reduce the hypoxic region, it will still be beneficial to include hypoxia 
information from before treatment in the treatment plans (Lin et al 2008). 
Methods proposed for overcoming hypoxia during radiotherapy treatment 
is, as mentioned in Section 3.3, dose painting, LET painting and including the OER in 
biological dose calculations (as done in Paper IV and V). The last method has the 
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benefit of also having the possibility of directly including a variable RBE in the 
calculations. To quantify which method is best, tumor control probability (TCP) 
models and normal tissue complication probability models can be applied, as these 
types of models are commonly used to assess the outcome of radiotherapy 
(McNamara et al 2019). Malinen and Søvik (2015) estimated the TCP of dose and 
LET painting for protons, lithium ions and carbon ions and concluded that the 
clinical impact of LET painting was smaller than that of dose painting. Also, while 
combined dose and LET painting gave the highest TCPs overall, the increased effect 
was not substantial compared to dose painting alone.  
The OER decreases with increasing RBE, and carbon ions are therefore more 
effective in killing hypoxic tumors than protons and photons. Dose painting has 
therefore less of an effect in carbon ion therapy than proton therapy, as carbon 
ions are already quite effective without dose painting. This was observed by 
Malinen and Søvik (2015), and they also saw that LET painting had larger effect 
with carbon ions than protons. As the OER of carbon ions are lower than that of 
low-LET radiation like photons, the carbon RBE will be increased in hypoxic regions. 
The hypoxia tools created in Paper IV and V may be useful for further exploration of 






Particle therapy is an established alternative to conventional radiotherapy for many 
cancer types, with dosimetric advantages which makes it possible to better confine 
the dose to the tumor. However, uncertainties in the RBE and biological dose is a 
limitation which must be reduced for particle therapy to reach its full potential.  
By decreasing the uncertainties in in vitro RBE data, more accurate RBE 
models can be obtained. The Monte Carlo simulations of the OCL experiment 
showed a steep increase of LETd values around the Bragg peak, combined with 
steep dose gradients. This demonstrates that high spatial and dosimetric precision, 
obtained through accurate implementation of the beamline in a Monte Carlo code, 
is essential for correct assessment of the LETd during cell irradiation experiments.  
The implementation of the MKM in FLUKA has made direct comparisons of 
different RBE models possible. Having the possibility of direct comparisons 
between European and Japanese carbon ion dose distributions is beneficial when 
comparing clinical protocols. While uncertainties in the biological dose estimates 
are high, as shown by the significantly different dose distributions estimated by the 
models, uncertainties in the MKM parameters was shown to have a smaller impact 
on the estimated dose than the percentage uncertainty in the parameters. 
A biological dose calculation method which accounts for both the OER and 
the RBE was developed and implemented in FLUKA and in a FLUKA based 
treatment planning tool. Underdosage of the tumor volume was seen when not 
accounting for hypoxia. However, optimization of treatment plans with the hypoxia 
model showed good potential for treatment planning, with the median target dose 
equal to the prescription dose and with increased physical dose in hypoxic regions.  
Overall, this thesis has contributed to the knowledge on the RBE and 
biological dose calculations in proton and carbon ion therapy. With the increase in 
particle therapy facilities worldwide, including the upcoming startup of two 
Norwegian proton centers, improving the accuracy of RBE and biological dose 
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